MedDataX Logo

Tailored Exercise Training Study Among Adults With HFpEF

NCT ID: NCT07223242

Last Updated: 2025-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-18

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers.

This study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare four different lifestyle interventions for their effects on exercise capacity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart failure (HF) portends substantial morbidity, mortality, and health care costs in the United States and the prevalence of heart failure with preserved ejection fraction (HFpEF) relative to HF with reduced ejection fraction (HFrEF) has been increasing. HFpEF is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. It is now recognized as a systemic, multi-organ, geriatric syndrome, with exercise intolerance (EI) and functional impairment as the key clinical manifestations. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers.

This study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare the effects of four different lifestyle interventions on exercise capacity.

The study will be carried out in two phases. In Phase I, 120 participants will undergo three months of home-based moderate-intensity continuous training (MCT), using tailored exercise videos on a mobile or tablet. Participants will also have weekly virtual meetings with a coach to discuss their progress. This will be followed by 3 months of no intervention, to assess the effects of detraining.

In Phase II (at the 6-month mark), 100 participants will be randomized to one of four extended training strategies for 3 months -(i) MCT alone; (ii) MCT plus resistance training; (iii) MCT plus weight loss, or (iv) MCT plus resistance training and weight loss.

The co-primary outcomes are (1) peak VO2, and (2) short physical performance battery score. In addition, participants will undergo CT chest/abdomen/pelvis at 3 months and 6 months to assess change in skeletal muscle composition with MCT

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HFpEF - Heart Failure With Preserved Ejection Fraction Diabetic Cardiomyopathies

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Diabetic cardiomyopathy Remote exercise training Weight loss Rehab

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be randomized in a 1:1:1:1 fashion for phase 2
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moderate-intensity continuous training (MCT)

Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

Group Type ACTIVE_COMPARATOR

Moderate-intensity continuous training (MCT)

Intervention Type BEHAVIORAL

Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

Moderate-intensity continuous training + weight loss

Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + initiation/intensification of pharmacological weight loss

Group Type EXPERIMENTAL

Moderate-intensity continuous training (MCT)

Intervention Type BEHAVIORAL

Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

Weight loss

Intervention Type DRUG

Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide

Moderate-intensity continuous training + resistance training

Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + tailored resistance training videos

Group Type EXPERIMENTAL

Moderate-intensity continuous training (MCT)

Intervention Type BEHAVIORAL

Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

Resistance training

Intervention Type BEHAVIORAL

Resistance training videos assigned to patient

Moderate-intensity continuous training + resistance training + weight loss

Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + tailored resistance training videos + initiation/intensification of pharmacological weight loss

Group Type EXPERIMENTAL

Moderate-intensity continuous training (MCT)

Intervention Type BEHAVIORAL

Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

Resistance training

Intervention Type BEHAVIORAL

Resistance training videos assigned to patient

Weight loss

Intervention Type DRUG

Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moderate-intensity continuous training (MCT)

Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

Intervention Type BEHAVIORAL

Resistance training

Resistance training videos assigned to patient

Intervention Type BEHAVIORAL

Weight loss

Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age\>= 18 yrs
2. LVEF (Left Ventricular Ejection Fraction) \>= 50%
3. History of HFpEF or at risk of HFpEF

1. HFpEF diagnosis based on:- -HF hospitalization within 12 months-

* NT-proBNP \>360 pg/mL
2. Risk of HFpEF based on:-

* \>2 risk factors (h/o diabetes, hypertension, obesity, physical inactivity by self-report)
4. SPPB \< 10 or VO2\<60th percentile
5. BMI \>=28 (for randomization in phase II)
6. Able to use cell phone and mobile application

Exclusion Criteria

1. Hospitalization 1 month prior to baseline visit
2. History of recurrent falls
3. eGFR (Estimated Glomerular Filtration Rate) \<20ml/min/1.73m
4. Active changes in HF therapies over 2 weeks prior to baseline visit
5. Inability participate in exercise training therapy
6. Inability to perform CPET (Cardiopulmonary Exercise Testing) testing
7. Severe left side valvular heart disease
8. End stage pulmonary disease, requiring continuous supplemental oxygen
9. Major surgery within 3 months of screening or major elective surgery during the duration of the study.
10. Unstable weight defined by \>5% change in body weight in last 30 days before first study visit.
11. Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Texas Southwestern Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ambarish Pandey

Associate Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ambarish Pandey, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STU-2024-0592

Identifier Type: -

Identifier Source: org_study_id